Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,227 recruiting studies in this area right now.
By phase
- Not applicable3,140
- Phase 21,067
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4236
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis342
- Multiple Myeloma333
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes132
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona140
- New York122
- Massachusetts119
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,227 total
- NCT06398873Recruiting
Dupilumab and nasal lining in chronic sinusitis with polyps
This study tests whether dupilumab, a medication given as an injection, helps improve the lining of the nose in people with chronic sinus inflammation and nasal polyps. If you have nasal polyps and are about to start dupilumab, or if you have sinusitis without polyps, you may be eligible to join.
Vienna, AustriaAges 18–99 - NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT06829355RecruitingPhase 2
Thymalfasin plus triple therapy for advanced colorectal cancer
This trial tests a combination of three drugs plus thymalfasin, an immune-boosting medicine, for people whose advanced colorectal cancer has not responded to at least two prior treatments. It's designed specifically for the common type of colorectal cancer (pMMR/MSS) to see if adding this immune therapy can help.
Beijing, ChinaAges 18–75 - NCT07693881Recruiting
Preventing EBV reactivation with rituximab after stem cell transplant in children
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
GuangzhouAges Up to 18 years - NCT07690787RecruitingPhase 2
Study of JS207 for nasopharyngeal cancer
This trial tests a new drug, JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow. It's for people with nasopharyngeal cancer that has not spread too much, and who have not had certain prior treatments.
Hong KongAges 18 years+ - NCT06342128Recruiting
Molecular study of inflammation in kidney transplants
This study looks at molecular changes in kidney transplants that have microvascular inflammation (a type of injury). It aims to better understand why some transplants get this inflammation, which could lead to better treatments.
ParisAges 18–100 - NCT06754605RecruitingPhase 1/Phase 2
Testing a new RSV vaccine for safety and immune response
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
Langfang, HebeiAges 18–120 - NCT06224257RecruitingPhase 2
Linperlisib for relapsed or refractory T-LGLL
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
Hefei, AnhuiAges 18 years+ - NCT06346912RecruitingEarly Phase 1
CAR-T cell therapy for relapsed B-cell blood cancers
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT07125586Recruiting
Light-based test for eosinophilic nasal polyps during surgery
This study tests a new tool that uses light (spectroscopy) to instantly detect a type of nasal polyp during surgery. The goal is to help doctors identify polyps that are driven by eosinophils, which may guide better treatment choices for you.
Qingdao, ShandongAges 18–65 - NCT05428826RecruitingPhase 4
Stopping steroids early if PET/CT looks negative
This study tests whether some people with idiopathic retroperitoneal fibrosis can stop prednisone earlier when a PET/CT scan shows no concerning activity. It may reduce steroid side effects while keeping the disease under control.
Agen, FranceAges 18 years+ - NCT00339287Recruiting
Healthy adults donate blood to study bacteria-fighting cells
This study looks at how a person’s immune cells interact with bacterial germs. You’d be screened as healthy and may donate blood (and possibly tissue), with samples stored for future research.
Hamilton, MontanaAges 18–120 - NCT06240689RecruitingPhase 2
Immune maintenance therapy after chemoradiotherapy for head and neck cancer
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
Hangzhou, ZhejiangAges 18–75 - NCT03458429Enrolling by invitationPhase 1/Phase 2
Plasma from healthy donors for frailty and immune health
This Phase 1/2 study tests whether transfusions of donated plasma can improve frailty and immune function in older adults. It mainly checks safety first, and also looks for signs that the immune system and overall strength may improve.
Boynton Beach, FloridaAges 55–95 - NCT01266915Recruiting
Cutaneous lupus skin disease registry study
This study builds a registry (a protected medical record) of people with cutaneous lupus and/or systemic lupus that affects the skin. It gathers skin exam information and may include a skin biopsy and blood tests to better understand these conditions.
Dallas, TexasAges 18 years+ - NCT07079735RecruitingPhase 2/Phase 3
Preventing CMV after heart transplant
This trial compares two antiviral drugs, valganciclovir and letermovir, to see which works better at preventing CMV infection after a heart transplant. If you've had a heart transplant and haven't started preventive treatment yet, this study may be for you.
New York, New YorkAges 18–99 - NCT06182969RecruitingPhase 1/Phase 2
APG-2575 for mild to moderate lupus
This trial tests an experimental drug called APG-2575 for people with mild to moderate lupus. It aims to see if the drug can help control lupus activity and improve symptoms.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06258551Recruiting
Tracking hard-to-treat bacteria in ICU and transplant patients
This study will track how certain hard-to-treat bacteria spread and cause infections in people who are in the intensive care unit (ICU) or have had a stem cell transplant. The goal is to better understand and prevent these infections in vulnerable patients.
Houston, TexasAges 18 years+ - NCT07297394Recruiting
How the immune system supports early pregnancy
This study looks at how the immune system helps the body accept a pregnancy. It involves blood samples from people who are pregnant or going through IVF/ICSI, or who have had a miscarriage.
BaselAges 18 years+ - NCT06281184Enrolling by invitation
Long-term follow-up of methotrexate for hand osteoarthritis
This study follows up on people who took part in the MERINO trial to see if methotrexate has lasting benefits for hand osteoarthritis. It aims to understand how the drug affects pain and joint health over 30 months.
OsloAges 18 years+ - NCT03148743Recruiting
Fecal transplant for gut graft-versus-host disease
This study tests whether a fecal transplant (FMT) can help treat gut graft-versus-host disease (gut GVHD), a condition where donated immune cells attack the intestines. If you have gut GVHD and meet age requirements, you may be eligible to receive this treatment in the trial.
Suzhou, JiangsuAges 10–60 - NCT07409103RecruitingPhase 2
Testing ELV001 for active rheumatoid arthritis
This study tests a new medication, ELV001, for people with active rheumatoid arthritis who haven't improved enough with methotrexate and a TNF inhibitor. The goal is to see if different doses of ELV001 are safe and can help reduce joint pain and swelling.
Gilbert, ArizonaAges 18–75 - NCT06794970Recruiting
Tissue study for chronic kidney transplant rejection
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
Bologna, BOAges 18 years+ - NCT07636525Recruiting
Sleep and Teen Vaccine Response Study
This study looks at how sleep affects how well a meningococcal vaccine works in 11–12 year olds. Researchers want to understand if getting good sleep helps your body respond better to vaccines.
Cincinnati, OhioAges 11–12
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,227 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,696 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.